1. Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment.
- Author
-
Penna, Domenico, Tieghi, Alessia, Valli, Riccardo, and Merli, Francesco
- Subjects
MYELOFIBROSIS ,RUXOLITINIB ,THERAPEUTICS ,EXTRAMEDULLARY hematopoiesis ,BODY temperature ,MAGNETIC resonance angiography - Abstract
Allogeneic bone marrow transplant is the only potentially curative treatment, while drug therapies aim only to reduce spleen size, constitutional symptoms, and anemia [[4]]. Standard treatment for AMF involves corticosteroids and immunosuppressive therapies [[9]]. Bone marrow fibrosis (BMF) is usually associated with malignant neoplasms (mainly by myeloproliferative disorders), but in a minority of cases, it is due to non-neoplastic causes [[1]]. Taking the above into account, in September 2015, after six months of steroid suspension and 18 months of continuous Ruxolitinib treatment, it was decided to reevaluate the disease to verify if a clonal process caused the BMF or if the fibrosis was associated with the autoimmune disease. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF